TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05661942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium pre-treatment
Description: The intervention is Calcium gluconate 1 gram/100ml 0.9% NaCl or 100ml 0.9% NaCl) over 5 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo/ no calcium pre-treatment.
Study: NCT05198934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Sotorasib will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Sotorasib will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab will be administered as intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab will be administered as intravenous (IV) infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trifluridine and Tipiracil
Description: Trifluridine and Tipiracil will be administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: Regorafenib will be administered orally
Study: NCT05389553

Intervention type: OTHER
Intervention: Ultrasound exam
Description: We included all full-term pregnancies accepted for delivery that received an accurate ultrasound scan before the birth
Study: NCT05206747

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue-blocking glasses
Description: It will transmit 45% of visible light with the following light transmission profile.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Lightly-tinted glasses
Description: It will also filter short wavelength light but at a lower threshold with near identical transmission above this threshold. It will transmit 91% of visible light with the following light transmission profile.
Study: NCT05481658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphencyprone (DPCP)
Description: topical immunomodulator
Study: NCT05881408

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: delandistrogene moxeparvovec
Description: Single IV infusion of delandistrogene moxeparvovec

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: delandistrogene moxeparvovec
Description: Single IV infusion of delandistrogene moxeparvovec

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single IV infusion of matching placebo

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single IV infusion of matching placebo
Study: NCT05281718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Factor IX
Description: Factor IX is on of the substrates of emicizumab.
Study: NCT06366451

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rilvegostomig
Description: Intratumoral microdose injection by the CIVO device.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Volrustomig
Description: Intratumoral microdose injection by the CIVO device.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sabestomig
Description: Intratumoral microdose injection by the CIVO device.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD9592
Description: Intratumoral microdose injection by the CIVO device.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intratumoral microdose injection by the CIVO device.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AZD9592 + Rilvegostomig
Description: Intratumoral microdose injection by the CIVO device.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AZD9592 + Volrustomig
Description: Intratumoral microdose injection by the CIVO device.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AZD9592 + Sabestomig
Description: Intratumoral microdose injection by the CIVO device.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AZD9592 + Pembrolizumab
Description: Intratumoral microdose injection by the CIVO device.
Study: NCT05540938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wangbi granules
Description: Methotrexate 7.5-15mg qw plus tofacitab 5mg bid, combined with Wangbi granules 12.0g tid, treatment course 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wangbi granules simulant
Description: Methotrexate 7.5-15mg qw plus tofacitab 5mg bid, combined with Wangbi granules simulant 12.0g tid, treatment course 3 months.
Study: NCT05617677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT06418321

Intervention type: DEVICE
Intervention: Investigational device
Description: The participants' hearing status will be evaluated using the investigational device.

Intervention type: DEVICE
Intervention: Investigational device
Description: The participants' hearing status will be evaluated using the investigational device.

Intervention type: OTHER
Intervention: Audiometer
Description: Participants' hearing thresholds are tested with an audiogram.

Intervention type: DEVICE
Intervention: Otomicroscopy
Description: The status of the participants' ear canals and tympanic membranes are checked.

Intervention type: OTHER
Intervention: REM (Real Ear Measurements)
Description: The acoustic properties of the participants' ears will be measured during the interventions.
Study: NCT05369299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant Straumann® Pure Ceramic Two Piece Implant
Description: Dental implants are placed directly after tooth extraction in the extraction socket.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: two-piece titanium implant Neoss® ProActive Tapered Implant
Description: Dental implants are placed directly after tooth extraction in the extraction socket.
Study: NCT06017999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XG005 tablet
Description: Subjects will receive XG005 prior to surgery and every 12 hours for 72 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XG005 tablet
Description: Subjects will receive XG005 prior to surgery and every 12 hours for 72 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet
Description: Subjects will receive placebo prior to surgery and every 12 hours for 72 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Subjects will receive placebo prior to surgery and every 12 hours for 72 hours.
Study: NCT05636553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Individualised treatment using massage techniques such as longitudinal gliding, transverse gliding, digital ischemic pressure, transverse frictions, and transverse gliding.
Study: NCT05864651

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-exercise program
Description: The tele-exercise program focused on lunge movement with additional strengthening abdominal and lumbopelvic muscle training while maintaining neuromuscular control. The difficulty of training was adjusted every week according to the five-step mastery program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Fencing Exercise
Description: The conventional exercise was based on 'displacement', a basic footwork training in fencing. The Displacement is also basic footwork to approach the opponent. The Displacement consisted of seven movements including 'Marche', 'Retraite \& Rompre', 'Passe avant', 'Passe arrière', 'Bond en avant', 'Bond en arrière', and 'Balestra'.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Fencing Exercise
Description: The conventional exercise was based on 'displacement', a basic footwork training in fencing. The Displacement is also basic footwork to approach the opponent. The Displacement consisted of seven movements including 'Marche', 'Retraite \& Rompre', 'Passe avant', 'Passe arrière', 'Bond en avant', 'Bond en arrière', and 'Balestra'.
Study: NCT05872620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT06202066

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Incomplete Freund''s Adjuvant
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Incomplete Freund''s Adjuvant
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SVN53-67/M57-KLH Peptide Vaccine
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SVN53-67/M57-KLH Peptide Vaccine
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT05261633

Intervention type: DEVICE
Intervention: Diffusion Weighted Magnetic Resonance Imaging
Description: Diffusion-weighted (DW)-MRI has a unique ability to probe tissue microstructure without the need for ionizing radiation or intravenous contrast agents. DW-MRI of the abdomen is utilized in detection, staging, and treatment surveillance of malignancies, and has shown great promise in various other applications, including for the assessment of fibrosis in the liver, pancreas, kidneys, and other organs.

Intervention type: DEVICE
Intervention: Diffusion Weighted Magnetic Resonance Imaging
Description: Diffusion-weighted (DW)-MRI has a unique ability to probe tissue microstructure without the need for ionizing radiation or intravenous contrast agents. DW-MRI of the abdomen is utilized in detection, staging, and treatment surveillance of malignancies, and has shown great promise in various other applications, including for the assessment of fibrosis in the liver, pancreas, kidneys, and other organs.
Study: NCT05708547

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: at the beginning of the extracorporeal circulation, at the end of the extracorporeal circulation and at D1

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: at the beginning of the extracorporeal circulation, at the end of the extracorporeal circulation and at D1

Intervention type: PROCEDURE
Intervention: myocardial tissue samples
Description: use of usually harvested right auricular tissue

Intervention type: PROCEDURE
Intervention: myocardial tissue samples
Description: use of usually harvested right auricular tissue

Intervention type: OTHER
Intervention: Data collection
Description: pre-operative data: demographic data, severity scores, co-morbidities, treatments administered, collection of the presence and stage of arteriosclerotic disease, SYNTAX score Collection of data on the procedure Data from the clinical evaluation and daily biological examinations until D7 data from the follow-up consultation between D30 and D60: late complications, total length of stay in intensive care and hospital

Intervention type: OTHER
Intervention: Data collection
Description: pre-operative data: demographic data, severity scores, co-morbidities, treatments administered, collection of the presence and stage of arteriosclerotic disease, SYNTAX score Collection of data on the procedure Data from the clinical evaluation and daily biological examinations until D7 data from the follow-up consultation between D30 and D60: late complications, total length of stay in intensive care and hospital
Study: NCT06105190

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of premium monofocal IOL, LuxSmart (device under investigation)
Description: Patients will be implanted with study IOL in both eyes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of monofocal IOL, LuxGood (control device)
Description: Patients will be implanted with Control IOL in both eyes
Study: NCT05519956

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: level Ib-covering IMRT
Description: Patients who had level II involvement with extracapsular extension (ECE), and/or had a maximum nodal axial diameter (MAD) of greater than 2cm in level II.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: level Ib-sparing IMRT
Description: Patients who had level II involvement with extracapsular extension (ECE), and/or had a maximum nodal axial diameter (MAD) of greater than 2cm in level II.
Study: NCT06553079

Intervention type: OTHER
Intervention: Surgeon Satisfaction Self-Assessment Questionnaire for Shoulder Arthroscopy
Description: The intervention in this study involves the administration of the Surgeon Satisfaction Self-Assessment Questionnaire for Shoulder Arthroscopy, a newly developed tool designed to measure various aspects of surgeon satisfaction related to shoulder arthroscopy procedures.
Study: NCT05872932

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastric balloon implantation
Description: After diagnostic endoscopy if there is no any gastric pathology that would be contraindication for balloon placement a gastric balloon will be placed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastric balloon implantation
Description: After diagnostic endoscopy if there is no any gastric pathology that would be contraindication for balloon placement a gastric balloon will be placed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: botulinum toxin A injection
Description: After diagnostic endoscopy if there is no any gastric pathology that would be contraindication Botox injection and balloon placement, 200 U of Botox A will be injected to antrum and fundus. And 1 week later gastric balloon will be implanted
Study: NCT06787690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cohealyx
Description: Cohealyx application, followed by autologous split-thickness skin graft
Study: NCT06786390

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation protocol: FES
Description: Subjects diagnosed with CIP will follow the FES-based rehabilitation protocol
Study: NCT04843540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: Rifampin as oral capsule
Study: NCT05955144

Intervention type: DEVICE
Group type: OTHER
Intervention: Picterus JP
Description: Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is placed.
Study: NCT06376617

Intervention type: DEVICE
Group type: OTHER
Intervention: fibroptic bronchoscopy
Description: take bal through fibrooptic bronchoscopy and send for stain and culcure
Study: NCT04993703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: A total of 20 sessions physiotherapy sessions including hot pack, ultrasound, kinesiotaping and exercise program (tendon and nerve gliding exercises=2 times per day 3 sets of ten repetitions) will be applied.times per day 3sets of ten repetitions) will be applied.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Night Splinting
Description: A total of 20 sessions physiotherapy sessions including hot pack, ultrasound, night splinting and exercise program (tendon and nerve gliding exercises=2 times per day 3 sets of ten repetitions) will be applied.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: A total of 20 sessions physiotherapy sessions including hot pack, ultrasound and exercise program (tendon and nerve gliding exercises=2 times per day 3 sets of ten repetitions) will be applied.
Study: NCT04839198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Android Wear smartwatch
Description: All participants will wear an Android Wear smartwatch, and will complete ecological momentary assessments (EMA).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Android Wear smartwatch
Description: All participants will wear an Android Wear smartwatch, and will complete ecological momentary assessments (EMA).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Treatment
Description: Participants will have access to a Dashboard button in the InsightTM app that displays personalized statistics based on their progress and patterns in the study.The dashboard will update as more data is collected about the participant's smoking habits, starting in the pre-quit period and continuing through the post-quit period. Second, in the post-quit period, participants will receive treatment messages when the machine learning algorithm determines that they are at high risk for lapse.At the follow-up visit, participants will complete a survey to evaluate what they liked and disliked about the intervention, how accurate they thought the app was in predicting their risk, and how useful they found the dashboard.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: At Visit 2, participants will be asked to begin their attempt to quit smoking and will receive a 12-week supply of nicotine replacement therapy (i.e., nicotine patches and gum)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patch
Description: At Visit 2, participants will be asked to begin their attempt to quit smoking and will receive a 12-week supply of nicotine replacement therapy (i.e., nicotine patches and gum)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interviewing-based counseling
Description: At Visit 2, participants will be asked to begin their attempt to quit smoking and meet with a Tobacco Treatment Specialist, who will provide motivational interviewing-based counseling, help the participants develop a quit plan, and discuss relapse prevention. During the 6-weeks of the study, participants will have the option of attending up to 6 counseling sessions with the Tobacco Treatment Specialist, either in-person or via phone or web.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: interviewing-based counseling
Description: At Visit 2, participants will be asked to begin their attempt to quit smoking and meet with a Tobacco Treatment Specialist, who will provide motivational interviewing-based counseling, help the participants develop a quit plan, and discuss relapse prevention. During the 6-weeks of the study, participants will have the option of attending up to 6 counseling sessions with the Tobacco Treatment Specialist, either in-person or via phone or web.
Study: NCT06342856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: co enzyme Q10 , L- Carnitine
Description: Patient fulfilling inclusion criteria after obtaining consent will be randomized into four equal groups randomization will be computer based

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: co enzyme Q10 , L- Carnitine
Description: Patient fulfilling inclusion criteria after obtaining consent will be randomized into four equal groups randomization will be computer based

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: co enzyme Q10 , L- Carnitine
Description: Patient fulfilling inclusion criteria after obtaining consent will be randomized into four equal groups randomization will be computer based

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: co enzyme Q10 , L- Carnitine
Description: Patient fulfilling inclusion criteria after obtaining consent will be randomized into four equal groups randomization will be computer based
Study: NCT06612502

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Static stretching
Description: The static stretching protocol comprised eight exercises, performed for 30 seconds per bilateral muscle group (with the exception of the sitting toe touch and butterfly stretch), and included the hip, knee, and ankle. The subjects were instructed to perform the following sequence of stretches: forward lunge, supine knee flexion, lateral quadriceps stretch, sitting toe touch, semi-straddle, straddle, butterfly stretch, and a straight knee ankle extensor wall stretch. Each subject completed each stretch before progressing to the subsequent one. The stretches were maintained until the subject experienced mild discomfort, but not pain.
Study: NCT06786390

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation protocol without FES
Description: Subjects belonging to the control group will follow the rehabilitation protocol without FES

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation protocol without FES
Description: Subjects belonging to the control group will follow the rehabilitation protocol without FES

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation protocol: FES
Description: Subjects diagnosed with CIM will follow the FES-based rehabilitation protocol
Study: NCT06783192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8527
Description: MK-8527 capsule taken by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNG/EE
Description: LNG/EE combination tablet taken by mouth.
Study: NCT06784648

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab (KEYTRUDA®)
Description: fixed dose 200mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BI-1607
Description: Each cohorts will receive either 350mg or 700mg per cycle for 4 cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab (YervoyTM, 50 mg/10 mL solution)
Description: Each cohort will receive either 1mg/kg or 3mg/kg for 4 cycles
Study: NCT06785922

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stomach biopsy for gastric microbiota
Description: Stomach biopsy for gastric microbiota testing (16S RNA sequencing)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stomach biopsy for gastric microbiota
Description: Stomach biopsy for gastric microbiota testing (16S RNA sequencing)